The Antinociceptive Effects of Nicotinic Partial Agonists Varenicline and Sazetidine-A in Murine Acute and Tonic Pain Models

Overview

Journal J Pharmacol Exp Ther

Specialty Pharmacology

Date 2012 Jun 9

PMID 22678099

Citations 23

Authors

Shakir D AlSharari

F Ivy Carroll

J Michael McIntosh

M Imad Damaj

Affiliations

Soon will be listed here.

Abstract

Nicotinic agonists display a wide-range profile of antinociceptive activity in acute, tonic, and chronic pain models. However, their effectiveness is limited by their unacceptable side effects. We investigated the antinociceptive effects of two new α4β2* nicotinic partial agonists, varenicline and sazetidine-A, in acute thermal and tonic pain mouse models. Both drugs failed to induce significant effects in the tail-flick and hot-plate tests after subcutaneous administration. However, they blocked nicotine's effects in these tests at very low doses. In contrast to acute pain tests, varenicline and sazetidine-A dose-dependently induced an analgesic effect in the mouse formalin test after systemic administration. Their antinociceptive effects were mediated, however, by different nicotinic acetylcholine receptor (nAChR) subtypes. Sazetidine-A effects were mediated by β2* nAChR subtypes, whereas varenicline actions were attributed to α3β4 nAChRs. Moreover, low inactive doses of varenicline blocked nicotine's actions in phase II of the formalin test. Overall, our results suggest that the antagonistic actions of varenicline at low doses are mediated by β2*-nAChRs and at higher doses as an agonist by α3β4*-nAChRs. In contrast, both actions of sazetidine-A are mediated by β2*-nAChR subtypes. These results suggest that nicotinic partial agonists possess analgesic effects in a rodent tonic pain model and may provide a potential treatment for the treatment of chronic pain disorders.

Citing Articles

New Pharmacological Insight into Etanercept and Pregabalin in Allodynia and Nociception: Behavioral Studies in a Murine Neuropathic Pain Model.

Alothman L, Alhadlaq E, Alhussain A, Alabdulkarim A, Sari Y, AlSharari S Brain Sci. 2024; 14(11).

PMID: 39595909 PMC: 11591859. DOI: 10.3390/brainsci14111145.

Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy.

Hu Y, Girdenyte M, Roest L, Liukkonen I, Siskou M, Ballgren F Fluids Barriers CNS. 2024; 21(1):13.

PMID: 38331886 PMC: 10854123. DOI: 10.1186/s12987-024-00519-7.

Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence.

Oliveira D, Fontenele R, Weleff J, Sofuoglu M, Aquino J Int Rev Psychiatry. 2024; 35(5-6):377-396.

PMID: 38299655 PMC: 10835074. DOI: 10.1080/09540261.2023.2229430.

Desensitizing nicotinic agents normalize tinnitus-related inhibitory dysfunction in the auditory cortex and ameliorate behavioral evidence of tinnitus.

Ghimire M, Cai R, Ling L, Brownell K, Wisner K, Cox B Front Neurosci. 2023; 17:1197909.

PMID: 37304018 PMC: 10248052. DOI: 10.3389/fnins.2023.1197909.

Consensus statement on smoking cessation in patients with pain.

Iida H, Yamaguchi S, Goyagi T, Sugiyama Y, Taniguchi C, Matsubara T J Anesth. 2022; 36(6):671-687.

PMID: 36069935 PMC: 9666296. DOI: 10.1007/s00540-022-03097-w.

References

Tjolsen A, Berge O, Hunskaar S, Rosland J, Hole K . The formalin test: an evaluation of the method. Pain. 1992; 51(1):5-17. DOI: 10.1016/0304-3959(92)90003-T. View

Mao D, Perry D, Yasuda R, Wolfe B, Kellar K . The alpha4beta2alpha5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. J Neurochem. 2007; 104(2):446-56. DOI: 10.1111/j.1471-4159.2007.05011.x. View

Damaj M, Welch S, Martin B . In vivo pharmacological effects of dihydro-beta-erythroidine, a nicotinic antagonist, in mice. Psychopharmacology (Berl). 1995; 117(1):67-73. DOI: 10.1007/BF02245100. View

Xiao Y, Fan H, Musachio J, Wei Z, Chellappan S, Kozikowski A . Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol. 2006; 70(4):1454-60. DOI: 10.1124/mol.106.027318. View

Abbott F, Franklin K, Westbrook F . The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain. 1995; 60(1):91-102. DOI: 10.1016/0304-3959(94)00095-V. View

Cunningham C, McMahon L . The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation. Eur J Pharmacol. 2010; 654(1):47-52. PMC: 3061304. DOI: 10.1016/j.ejphar.2010.12.003. View

Carroll F, Yokota Y, Ma W, Lee J, Brieaddy L, Burgess J . Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3'-(substituted phenyl)deschloroepibatidine analogs. Bioorg Med Chem. 2007; 16(2):746-54. PMC: 2374917. DOI: 10.1016/j.bmc.2007.10.027. View

Corringer P, Le Novere N, Changeux J . Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol. 2000; 40:431-58. DOI: 10.1146/annurev.pharmtox.40.1.431. View

Iwamoto E, MARION L . Adrenergic, serotonergic and cholinergic components of nicotinic antinociception in rats. J Pharmacol Exp Ther. 1993; 265(2):777-89. View

10.

Luo S, Kulak J, Cartier G, Jacobsen R, Yoshikami D, Olivera B . alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J Neurosci. 1998; 18(21):8571-9. PMC: 6793526. View

11.

Damaj M, Dukat M, Glassco W, Glennon R, Martin B . Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther. 1998; 284(3):1058-65. View

12.

Turner J, Castellano L, Blendy J . Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior. J Pharmacol Exp Ther. 2010; 334(2):665-72. PMC: 2913767. DOI: 10.1124/jpet.110.166280. View

13.

Watson G, Sufka K, Coderre T . Optimal scoring strategies and weights for the formalin test in rats. Pain. 1997; 70(1):53-8. DOI: 10.1016/s0304-3959(96)03299-x. View

14.

Flores C, Wilson S, Mogil J . Pharmacogenetic variability in neuronal nicotinic receptor-mediated antinociception. Pharmacogenetics. 1999; 9(5):619-25. View

15.

Papke R, Trocme-Thibierge C, Guendisch D, Al Rubaiy S, Bloom S . Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists. J Pharmacol Exp Ther. 2011; 337(2):367-79. PMC: 3083103. DOI: 10.1124/jpet.110.177485. View

16.

Gao B, Hierl M, Clarkin K, Juan T, Nguyen H, van der Valk M . Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain. Pain. 2010; 149(1):33-49. DOI: 10.1016/j.pain.2010.01.007. View

17.

Cucchiaro G, Chaijale N, Commons K . The dorsal raphe nucleus as a site of action of the antinociceptive and behavioral effects of the alpha4 nicotinic receptor agonist epibatidine. J Pharmacol Exp Ther. 2004; 313(1):389-94. DOI: 10.1124/jpet.104.079368. View

18.

Perkins K, Grobe J, Fonte C, Goettler J, Caggiula A, REYNOLDS W . Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans. J Pharmacol Exp Ther. 1994; 270(2):628-38. View

19.

Iwamoto E . Characterization of the antinociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus. J Pharmacol Exp Ther. 1991; 257(1):120-33. View

20.

Gillberg P, dArgy R, Aquilonius S . Autoradiographic distribution of [3H]acetylcholine binding sites in the cervical spinal cord of man and some other species. Neurosci Lett. 1988; 90(1-2):197-202. DOI: 10.1016/0304-3940(88)90811-7. View